Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01091142 · ClinicalTrials.gov registry record · Phase 1
Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)
A Phase 1 study, sponsored by Neuraltus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
NCT01091142 is a Phase 1 study that has completed, run by Neuraltus Pharmaceuticals. The registered enrollment target is 56 participants.
The verdict
NCT01091142, a Phase 1 study, has completed, sponsored by Neuraltus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
Study Summary
Primary objectives: To assess the safety and tolerability of ascending doses of NP001 compared to placebo in subjects with ALS. Secondary objective: To explore the effects of NP001 on biomarkers potentially relevant to ALS.
Interventions
- DRUG Placebo
- DRUG NP001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01091142
The ClinicalTrials.gov registry entry for NCT01091142 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Neuraltus Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01091142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01091142 about?
NCT01091142 is a clinical study titled "Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)". Primary objectives: To assess the safety and tolerability of ascending doses of NP001 compared to placebo in subjects with ALS. Secondary objective: To explore the effects of NP001 on biomarkers potentially relevant to ALS.
What is the current status of trial NCT01091142?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2010-07.
What interventions are being tested in trial NCT01091142?
The interventions under investigation include: Placebo (DRUG), NP001 (DRUG).
Who is sponsoring clinical trial NCT01091142?
This trial is sponsored by Neuraltus Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.